Durvalumab Promising for NSCLC [News in Brief]

Checkpoint inhibitor increases progression-free survival, response rate in patients with stage III non–small cell lung cancer.

from Cancer via ola Kala on Inoreader http://ift.tt/2fyFxRi
via IFTTT